24 Jan 2023 , 12:15 PM
Dr. Reddy’s Laboratories could post healthy growth in US sales during the quarter, following continued momentum in niche products. Domestic business could post 6-7% revenue growth over the year-ago quarter, with gastro, respiratory and cardiac therapies taking the lead. Analysts at IIFL Capital Services expect revenue to grow 17% over the year-ago quarter and decline 2% sequentially. Exluding Revlimid, growth could be subdued.
Key margin pressures include price pressures in US, high input cost inflation and integration of low-margin Cidmus brand in India.
The company is likely to post 39% in Profit After Tax (PAT) over the year-ago quarter.
Important management insights to watch out for:
December 2022 estimates |
YoY change |
QoQ change |
|
Revenue (Rs mn) |
62,016 |
17% |
(2)% |
EBITDA (Rs mn) |
15,339 |
28% |
(15)% |
EBITDA margin |
24.7% |
214 bps |
(383) bps |
Profit After Tax (Rs mn) |
9,919 |
39% |
(3)% |
Source: IIFL Research
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.